See What HealthDay Can Do For You
Contact Us

Over 50 FDA-Approved Meds Can Help Battle Ebola Infection

Researchers uncover 53 potential treatments; more study for this use needed

WEDNESDAY, Dec. 17, 2014 (HealthDay News) -- A screening test has identified more than 50 U.S. Food and Drug Administration-approved medications that could be helpful in treating people with Ebola, researchers report. The study was published online Dec. 17 in Emerging Microbes and Infections.

The screening test involves a laboratory-engineered Ebola virus which contains two proteins from the pathogen, but does not include the infectious genetic material that makes Ebola so dangerous, study author Adolfo Garcia-Sastre, Ph.D., director of the Global Health and Emerging Pathogens Institute with the Icahn School of Medicine at Mount Sinai in New York City, told HealthDay. This Ebola-like particle can enter human cells as the actual virus does. It provides a safe and effective way for researchers to test drugs that might block Ebola from entering cells, he said.

The researchers used this engineered Ebola virus to screen a panel of 600 FDA-approved drugs. These drugs were originally prepared for a cancer treatment project, according to background information from the study. The researchers also did a follow-up screening on 2,816 compounds. From these samples, the researchers identified 53 drugs with potential. These drugs fall into six different categories, including antihistamines, antipsychotics, and anticancer/antibiotic medications.

"These drugs are all approved, so they could be deployed quickly if follow-up research proves that they are effective," Garcia-Sastre said.

Full Text

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.